araag2/HINT huggingface dataset:
Clinical trial NCT00216593 (phase 3, status: completed)
Conditions: dementia, alzheimer disease
ICD codes: G31.09, G31.83, F01.50, F01.51, F03.90, F03.91, F18.17, G30.8, G30.9, G30.0, G30.1
Drugs: galantamine hydrobromide
SMILES: [H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Alzheimer's type dementia, rated as severe

          -  progressive worsening of memory and other cognitive functions

          -  brain imaging (CTor MRI scan) within last 3 years

          -  ability to be mobile (aided or unaided) with sufficient vision and hearing to comply
             with testing.

        Exclusion Criteria:

          -  Dementia caused by cerebrovascular disease

          -  disturbances of consciousness, delirium, psychosis

          -  severe aphasia

          -  or major sensorimotor impairment

          -  cognitive impairment due to acute cerebral trauma, hypoxic cerebral damage, vitamin
             deficiency, infections, primary of metastatic cerebral neoplasia, endocrine or
             metabolic disease or mental retardation, pregnant or nursing women or those without
             adequate contraception.
Clinical trial NCT00343096 (phase 3, status: terminated)
Conditions: status epilepticus, convulsions
ICD codes: G40.803, G40.804, G40.823, G40.824, G40.833, G40.834, G40.911
Drugs: lorazepam
SMILES: CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
Reason stopped: 
    the buccal arm of the study was 30% less effective in stopping seizures within 10 minutes
    compared with the iv dose. this met a stopping rule for the study
  
Eligibility criteria:

        Inclusion Criteria:

        children with acute generalized seizures, continuing for a minimum of 5 minutes, who have
        not received any anti-convulsant therapy within 1 hour of presentation.

        Exclusion Criteria:

        Children who have received anticonvulsant treatment within 1 hour prior to assessment. Any
        child whose seizures cease following correction of hypoglycaemia. Children with a known
        adverse reaction to lorazepam.
Clinical trial NCT00459667 (phase 3, status: completed)
Conditions: multiple sclerosis, relapsing-remitting
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: interferon beta-1b (betaseron, bay86-5046), interferon beta-1b (betaseron, bay86-5046), interferon beta-1b (betaseron, bay86-5046)
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Completion of the BEYOND study 306440 as scheduled

          -  Relapsing multiple sclerosis

          -  Medical assessment by the investigator that there is no objection to the patient's
             participation in this trial considering the medical experience from study 306440.
             Special attention should be given to laboratory abnormalities and clinically relevant
             liver, renal and bone-marrow dysfunction.

          -  Females of child-bearing potential:

               -  Agreement to practice adequate contraception methods and

               -  Negative pregnancy test and

               -  No lactation

          -  Written informed consent

        Exclusion Criteria:

          -  Serious or acute heart diseases

          -  History of severe depression or suicide attempt

          -  Epilepsy not adequately controlled by treatment

          -  Known allergy to IFNs, to human albumin or to mannitol

          -  Medical, psychiatric or other conditions that compromise the patient's ability to
             understand the patient information, to give informed consent, to comply with the trial
             protocol, or to complete the study
Clinical trial NCT01529528 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: anagliptin, anagliptin, placebo of anagliptin
SMILES: CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N, CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 DM patients

          -  Subjects who couldn't control the blood glucose despite of a dietary and exercise
             therapy more than 6 weeks at screening visit

          -  FPG ≤ 270mg/dL at screening visit

          -  Patients who consent to participate in this trial by written Informed Consent Form

        Exclusion Criteria:

          -  Type 1 DM or secondary diabetes

          -  Subjects who are administrating insulin or need to insulin therapy

          -  History of oral anti-hyperglycemic drugs within 6 weeks before screening visit

          -  Body mass index < 20 kg/m2 or > 40.0kg/m2

          -  Subjects who are assessed to be inappropriate for this trial by investigator
Clinical trial NCT00731679 (phase 3, status: completed)
Conditions: non-constipation irritable bowel syndrome
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: rifaximin, placebo
SMILES: [H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed IBS diagnosis per Rome II for diagnosis of IBS.

          -  Colonoscopy within 2 years as part of IBS diagnostic evaluation.

          -  Has active symptoms of non-constipation IBS at baseline as measured by average daily
             scores for abdominal pain/discomfort, bloating, and stool consistency.

        Exclusion Criteria:

          -  Symptoms of constipation.

          -  History of other gastrointestinal diseases.

          -  Type 1 or 2 diabetes.

          -  Lactose intolerance not controlled by lactose-free diet.
Clinical trial NCT01164501 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2, renal insufficiency
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: bi 10773, placebo, placebo, bi 10773, placebo, placebo
SMILES: [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          1. Diagnosis of type 2 diabetes mellitus prior to informed consent and an estimated
             glomerular filtration rate of <90 ml/min.

          2. Male and female patients on diet and exercise regimen who are pre-treated with any
             antidiabetic therapy and are on the maximum tolerated dose which has been unchanged
             for 12 weeks prior to randomisation.

          3. HbA1c greater than or equal to 7.0% and less than or equal to 10.0% .

          4. Aged 18 years or above.

          5. Body Mass Index less than or equal to 45 kg/m2

        Exclusion criteria:

          1. Uncontrolled hyperglycaemia defined as >13.3 mmol/L after an overnight fast during
             placebo run-in.

          2. Impaired renal function, defined as an estimated glomerular filtration rate <15
             ml/min.

          3. Renal impairment requiring any form of chronic dialysis.

          4. Requiring acute dialysis within three months prior to informed consent.

          5. Renal transplant recipient.

          6. Myocardial infarction, stroke or Transient Ischemic Attack within three months prior
             to informed consent.

          7. Indication of liver disease.

          8. Bariatric surgery within the past two years.

          9. Medical history of cancer.

         10. Blood dyscrasias or any disorders causing hemolysis or unstable red blood cell.

         11. Contraindications to pre-existing background antidiabetic therapy.

         12. Treatment with anti-obesity drugs.

         13. Current treatment with systemic steroids or change in dosage of thyroid hormones
             within six weeks prior to informed consent or any other uncontrolled endocrine
             disorder except Type 2 Diabetes.

         14. Pre-menopausal women who are nursing or pregnant or are of child-bearing potential and
             are not practising an acceptable method of birth control.
Clinical trial NCT00384527 (phase 3, status: terminated)
Conditions: clostridium infections
ICD codes: A05.2, A04.71, A04.72, B96.7
Drugs: nitazoxanide, vancomycin
SMILES: CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O, CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O
Reason stopped: 
    study was terminated early due to slow recruitment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 18 years.

          -  Patients with new onset of disease evidenced by diarrhea (≥ 3 unformed stools within
             24 hours), and one or more of the following symptoms of CDAD:

               -  abdominal pain or cramps

               -  peripheral leukocytosis

               -  fever

          -  C. difficile toxin A or B detected in a stool specimen obtained within 3 days before
             enrollment by enzyme immunoassay.

          -  Patients willing to avoid the following medications during the study:

               -  oral and intravenous metronidazole

               -  oral vancomycin

               -  anti-peristaltic drugs

               -  opiates (patients on opiates may be included in the study if they were taking
                  opiates prior to enrollment and the dose is not increased during the study)

               -  Saccharomyces cerevisiae (baker's yeast)

               -  Lactobacillus GG

               -  cholestyramine

               -  colestipol

        Exclusion Criteria:

          -  Patients with other known causes of diarrhea or colitis (e.g., Shigella, Salmonella,
             Cryptosporidium parvum, Giardia lamblia, Entamoeba histolytica, inflammatory bowel
             disease, irritable bowel syndrome, advanced AIDS or chemotherapy for malignancy).

          -  Patients that commonly have 3 or more stools per day and/or severe abdominal pain in
             the absence of CDAD.

          -  Patients with severe lactose intolerance.

          -  Patients with more than 1 recurrence of CDAD during the 6 months prior to enrollment.

          -  Patients unable to take oral medications.

          -  Use within 1 week of enrollment of any drug or therapy with anti-C. difficile activity
             such as oral or intravenous metronidazole and oral vancomycin. [Patients that have
             taken up to 3 doses of metronidazole or vancomycin can be included in the study].

          -  Females of child bearing age who are either pregnant, breast-feeding or not using
             birth control and are sexually active.

          -  Patients who are either clinically unstable (e.g., fulminant disease patients with
             signs of toxic megacolon, imminent perforation, colectomy or death) or unlikely to
             live throughout the 31-day duration of the study due to underlying illness.

          -  History of hypersensitivity to nitazoxanide or vancomycin or any active ingredient in
             the formulations.
Clinical trial NCT01059799 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  For Japan only: minimum age is 20 years

          -  Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months

          -  Current treatment with monotherapy or combination of an insulin secretagouge
             (sulfonylurea or glinide) and metformin, with or without addition of
             alfa-glucosidase-inhibitors or a DPP-4 inhibitor with unchanged dosing for at least 3
             months prior to visit 1. The dose(s) should as minimum be as stated: -Insulin
             secretagogue (sulfonylurea or glinide): Minimum half of the daily maximal dose
             according to local labelling -Metformin: alone or in combination (including fixed
             combination): Maximum tolerated dose - alfa-glucosidase-inhibitors: Minimum half of
             the daily maximal dose or maximum tolerated dose -DPP-4 (dipeptyl peptidase 4)
             inhibitor: According to local labelling

          -  HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis

          -  Body Mass Index (BMI) no higher than 35.0 kg/m^2

        Exclusion Criteria:

          -  Use within the last 3 months prior to Visit 1 of: TZDs (thiazolidinediones), exenatide
             or liraglutide

          -  Cardiovascular disease, within the last 6 months prior to visit 1, defined as: stroke;
             decompensated heart failure New York Heart Association (NYHA) class III or IV;
             myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or
             angioplasty

          -  Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least
             180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)

          -  Pregnancy, breast-feeding, or the intention of becoming pregnant or not using adequate
             contraceptive measures according to local requirements (for Thailand: adequate
             contraceptive measures are: diaphragm, condom (by the partner), intrauterine device in
             place for last three months before trial starts, sponge, cap with spermicide,
             contraceptive patch, approved hormonal implant (i.e. Norplant), oral contraceptives
             taken without difficulty for the last three months before trial starts, post
             menopausal state or sterilisation.)

          -  Cancer and medical history of cancer (except basal cell skin cancer or squamous cell
             skin cancer)
Clinical trial NCT01421498 (phase 3, status: completed)
Conditions: keratoconjunctivitis sicca, dry eye disease
ICD codes: H16.223, H16.221, H16.222, H16.229, H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: lifitegrast, placebo
SMILES: CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C3=CC=C4C=COC4=C3)C=C2Cl)C(O)=O)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to read, sign, and date the informed consent and HIPAA documents

          -  Willing and able to comply with all study procedures

          -  Be at least 18 years of age

          -  Patient-reported history of dry eye in both eyes

          -  Demonstrate a positive response when exposed to the Controlled Adverse Environment
             model

          -  A negative urine pregnancy test if female of childbearing potential and must use
             adequate birth control throughout the study period

        Exclusion Criteria:

          -  Any ocular condition that, in the opinion of the Investigator, could affect study
             parameters including, but not limited to, active ocular infection, ocular
             inflammation, glaucoma, and/or diabetic retinopathy

          -  Unwilling to avoid wearing contact lenses for 7 days prior to and for duration of the
             study period

          -  Any blood donation or significant loss of blood within 56 days of Visit 1

          -  Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of
             acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.

          -  Use of any topical ophthalmic preparations (including artificial tear substitutes) 72
             hrs prior to Visit 1 and during the study

          -  Any significant chronic illness that could interfere with study parameters

          -  History of laser-assisted in situ keratomileusis (LASIK) or similar type of corneal
             refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical
             procedure within 12 months prior to Visit 1; or any scheduled ocular surgical
             procedure during the study period.

          -  Known history of alcohol and/or drug abuse

          -  Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet
             cells (as with Vitamin A deficiency)
Clinical trial NCT00105989 (phase 3, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: duloxetine, placebo
SMILES: CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient must be at least 18 years old.

          -  Patient must be diagnosed with depression and have had previous episodes of
             depression.

          -  Patient must sign informed consent.

        Exclusion Criteria:

          -  Female and pregnant or breastfeeding.

          -  History of bipolar disorder, schizophrenia, or other psychotic disorders.

          -  Suffer from a serious medical illness (other than depression) or abnormal laboratory
             result that would require a change in medication, intervention, or hospitalization.

          -  Have been treated with a medication called monoamine oxidase inhibitor (MAOI) within
             14 days of the start of the study, or potential need to use a MAOI within 5 days of
             finishing the study.

          -  Have taken an antidepressant called fluoxetine within 30 days of the start of the
             study.
Clinical trial NCT00430248 (phase 3, status: completed)
Conditions: gout
ICD codes: M10.9, M10.08, M10.00, M10.011, M10.012, M10.019, M10.021
Drugs: febuxostat, febuxostat, allopurinol
SMILES: CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N, CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N, O=C1N=CN=C2NNC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Has one or more of the American Rheumatism Association criteria for the diagnosis of
             gout.

          -  Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant nor lactating from Screening throughout the
             duration of the study.

          -  Must have a serum urate level greater than or equal to 8.0 milligram per deciliter
             (mg/dL).

        Exclusion Criteria:

          -  Have a severe, unstable, or life threatening medical condition that would likely
             prevent them from completing this study.

          -  Has a known body reaction to febuxostat, allopurinol, naproxen, any other
             non-steroidal anti-inflammatory drug (NSAID), aspirin, lansoprazole, colchicine, or
             any components in their formulation.

          -  History of xanthinuria.

          -  Alcohol consumption greater than 14/week.

          -  History of significant concomitant illness.

          -  Active liver or peptic ulcer disease.

          -  Has rheumatoid arthritis requiring treatment.

          -  Has estimated creatinine clearance less than 30 milliliter per minute (mL/min)
             calculated using the Cockcroft-Gault formula corrected for ideal body weight.

          -  Requires therapy with any other urate-lowering drug other than the study drug;
             long-term use of NSAIDs and COX-2 inhibitors; salicylates; thiazide diuretics;
             losartan; azathioprine; mercaptopurine; theophylline; intravenous (IV) colchicine;
             cyclosporine; cyclophosphamide; pyrazinamide; sulfamethoxazole;trimethoprim.
Clinical trial NCT00046462 (phase 3, status: completed)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: lantus (insulin glargine [rdna origin] injection), metformin, glyburide, thiazolidinedione
SMILES: CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N, O=C1CSC(=O)N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients between 18 - 79 years of age

          -  With diagnosed type 2 diabetes for at least a year treated with stable doses of two
             oral antidiabetic drugs of which one is either Avandia or Actos for at least three
             months

        Exclusion Criteria:

          -  Major cardiovascular events

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00697099 (phase 3, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: semuloparin sodium, enoxaparin sodium, placebo
SMILES: \N, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Elective total hip replacement surgery or a revision of at least one component of a
             prosthesis implanted ≥ 6 months prior to study entry.

        Exclusion Criteria:

          -  Any major orthopedic surgery in the 3 months prior to study start;

          -  Deep vein thrombosis or pulmonary embolism within the last 12 months or known
             post-phlebitic syndrome;

          -  High risk of bleeding;

          -  Known allergy to heparin or enoxaparin;

          -  Any contra-indications to the performance of venography;

          -  End stage renal disease or patient on dialysis.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00575588 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: metformin, sulphonylurea, saxagliptin
SMILES: CSCC[C@H](N)C(O)=O, N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes,

          -  Treatment with metformin alone on stable doses of 1500 mg or higher per day for at
             least 8 weeks prior to Visit 1,

          -  HbA1c >6.5% and ≤10.0%

        Exclusion Criteria:

          -  Type 1 diabetes,

          -  history of diabetic ketoacidosis or hyperosmolar non-ketonic coma,

          -  Insulin therapy within one year of enrolment (with the exception of insulin therapy
             during a hospitalization or use in gestational diabetes)